Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for lung fibrosis in mechanically ventilated severe COVID-19 pneumonia
jRCTs051200036Completed
- Sponsor
- Osaka General Medical Center
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of nintedanib in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Osaka General Medical Center. Primary endpoint: 28-day mortality after initiation of mechanical ventilation. Started Jul 2020; status: completed.
02
Drugs
nintedanib
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on jRCTs051200036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200036.